AU2009220137A1 - Use of mesenchymal stem cells for treating genetic diseases and disorders - Google Patents

Use of mesenchymal stem cells for treating genetic diseases and disorders Download PDF

Info

Publication number
AU2009220137A1
AU2009220137A1 AU2009220137A AU2009220137A AU2009220137A1 AU 2009220137 A1 AU2009220137 A1 AU 2009220137A1 AU 2009220137 A AU2009220137 A AU 2009220137A AU 2009220137 A AU2009220137 A AU 2009220137A AU 2009220137 A1 AU2009220137 A1 AU 2009220137A1
Authority
AU
Australia
Prior art keywords
gene
mesenchymal stem
stem cells
cells
mscs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009220137A
Other languages
English (en)
Inventor
Alla Danilkovitch
Charles R. Mills
Timothy R. Varney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mesoblast International SARL
Original Assignee
Mesoblast International SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mesoblast International SARL filed Critical Mesoblast International SARL
Publication of AU2009220137A1 publication Critical patent/AU2009220137A1/en
Priority to AU2015201881A priority Critical patent/AU2015201881A1/en
Assigned to Mesoblast International Sarl reassignment Mesoblast International Sarl Request for Assignment Assignors: OSIRIS THERAPEUTICS, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
AU2009220137A 2008-03-05 2009-03-04 Use of mesenchymal stem cells for treating genetic diseases and disorders Abandoned AU2009220137A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2015201881A AU2015201881A1 (en) 2008-03-05 2015-04-15 Use of mesenchymal stem cells for treating genetic diseases and disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/042,487 US20080286249A1 (en) 2006-01-12 2008-03-05 Use of mesenchymal stem cells for treating genetic diseases and disorders
US12/042,487 2008-03-05
PCT/US2009/001390 WO2009111030A1 (en) 2008-03-05 2009-03-04 Use of mesenchymal stem cells for treating genetic diseases and disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015201881A Division AU2015201881A1 (en) 2008-03-05 2015-04-15 Use of mesenchymal stem cells for treating genetic diseases and disorders

Publications (1)

Publication Number Publication Date
AU2009220137A1 true AU2009220137A1 (en) 2009-09-11

Family

ID=40635808

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009220137A Abandoned AU2009220137A1 (en) 2008-03-05 2009-03-04 Use of mesenchymal stem cells for treating genetic diseases and disorders

Country Status (10)

Country Link
US (8) US20080286249A1 (https=)
EP (1) EP2262513A1 (https=)
JP (1) JP6037597B2 (https=)
CN (1) CN102014936A (https=)
AU (1) AU2009220137A1 (https=)
BR (1) BRPI0909817A2 (https=)
CA (1) CA2717498A1 (https=)
MX (1) MX2010009767A (https=)
NZ (1) NZ587809A (https=)
WO (1) WO2009111030A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2471907T3 (pl) 2005-12-29 2019-07-31 Celularity, Inc. Populacje komórek macierzystych łożyska
KR20200011604A (ko) 2008-08-20 2020-02-03 안트로제네시스 코포레이션 개선된 세포 조성물 및 그의 제조 방법
CA2734446C (en) 2008-08-22 2017-06-20 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
RU2539786C2 (ru) 2008-09-02 2015-01-27 Плуристем Лтд. Выращенные в прикрепленной к субстрату культуре клетки из ткани плаценты и их использование при лечении
RU2015130665A (ru) 2008-11-19 2018-12-24 Антродженезис Корпорейшн Амниотические адгезивные клетки
WO2011064733A1 (en) * 2009-11-27 2011-06-03 Stempeutics Research Pvt. Ltd. Methods of preparing mesenchymal stem cells, compositions and kit thereof
US20110142805A1 (en) * 2009-12-15 2011-06-16 Advanced Technologies And Regenerative Medicine, Llc Method of renal repair and regeneration and the treatment of diabetic nephropathy
EP2555783A1 (en) 2010-04-08 2013-02-13 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
KR101903339B1 (ko) * 2011-03-22 2018-10-01 플루리스템 리미티드 방사선 또는 화학적 손상을 치료하는 방법
ES2707579T3 (es) 2011-06-01 2019-04-04 Celularity Inc Tratamiento del dolor usando citoblastos placentarios
WO2013055476A1 (en) * 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
CN103183736A (zh) * 2011-12-27 2013-07-03 北京和信非凡生物技术有限公司 一种抗clcn7蛋白的单克隆抗体及其应用
KR20150065697A (ko) * 2012-09-04 2015-06-15 안트로제네시스 코포레이션 조직 생성 방법
WO2014087658A1 (en) * 2012-12-07 2014-06-12 Kuraray Co., Ltd. Method of cell fusion and fusion cells
US20140271568A1 (en) 2013-03-12 2014-09-18 Hawking Biological Technology Co., Ltd Method and kit for providing an increased expression of telomerase, brain-derived neurotrophic factor, stromal cell-derived factor-1, cxc chemokine receptor 4, and/or immune regulatory factor of stem cell
CN104042606B (zh) * 2013-03-12 2017-05-24 国钦生物科技股份有限公司 苯酞化合物的应用
EP3151847B1 (en) * 2014-06-04 2020-07-29 Cedars-Sinai Medical Center Human mesenchymal stem cells and pth for use in a method for non surgical repair of vertebral compression fractures
CN104726496B (zh) * 2015-03-27 2017-07-07 中国科学院生物物理研究所 携带人类成年早衰症基因突变的多能干细胞及制备方法
JP6890553B2 (ja) * 2015-06-11 2021-06-18 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ 筋ジストロフィーキメラ細胞および筋ジストロフィーの処置方法
US10596298B2 (en) 2016-04-22 2020-03-24 Vivex Biologics Group, Inc. Malleable demineralized bone composition and method of manufacture
US11253629B2 (en) 2016-04-22 2022-02-22 Vivex Biologics Group, Inc. Bone gel sheet composition and method of manufacture
US10463767B2 (en) 2016-04-22 2019-11-05 Vivex Biologics Group, Inc. Moldable bone composition
US9788950B1 (en) 2016-04-22 2017-10-17 Vivex Biomedical, Inc. Cohesive bone composition
US11253630B2 (en) 2016-04-22 2022-02-22 Vivex Biologics Group, Inc. Malleable demineralized bone composition and method of manufacture
WO2018092769A1 (ja) 2016-11-15 2018-05-24 株式会社カネカ 胎児付属物に由来する間葉系幹細胞を含む細胞集団とその製造方法、及び医薬組成物
CN111406106A (zh) * 2017-11-28 2020-07-10 伊利诺伊大学理事会 多嵌合细胞以及移植疗法与免疫缺陷和遗传病症的治疗
WO2019132026A1 (ja) 2017-12-28 2019-07-04 株式会社カネカ 接着性幹細胞を含む細胞集団とその製造方法、及び医薬組成物
WO2020251020A1 (ja) 2019-06-14 2020-12-17 株式会社カネカ 間葉系細胞を含む細胞集団、それを含む医薬組成物、及び、その製造方法
WO2024183769A1 (en) * 2023-03-06 2024-09-12 Lingyi Biotech Co., Ltd. A truncated atp7b and the use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733542A (en) * 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6010696A (en) * 1990-11-16 2000-01-04 Osiris Therapeutics, Inc. Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US5635156A (en) * 1993-09-13 1997-06-03 University Of Pittsburgh Non-lethal methods for conditioning a recipient for bone marrow transplantation
US5591625A (en) * 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US6653134B2 (en) * 1995-03-28 2003-11-25 Cp Hahnemann University Isolated stromal cells for use in the treatment of diseases of the central nervous system
US6974571B2 (en) * 1995-03-28 2005-12-13 Thomas Jefferson University Isolated stromal cells and methods of using the same
US6962698B1 (en) * 1998-02-17 2005-11-08 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
AU749675B2 (en) * 1998-03-13 2002-07-04 Mesoblast International Sarl Uses for human non-autologous mesenchymal stem cells
AU755888B2 (en) * 1998-03-18 2003-01-02 Mesoblast International Sarl Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US7544509B2 (en) * 2000-01-24 2009-06-09 Mcgill University Method for preparing stem cell preparations
JPWO2003014336A1 (ja) * 2001-08-07 2004-11-25 麒麟麦酒株式会社 造血幹細胞の製造法
CA2460985C (en) * 2001-09-20 2016-01-05 Anticancer, Inc. Nestin-expressing hair follicle stem cells
US20050048036A1 (en) * 2001-12-07 2005-03-03 Hedrick Marc H. Methods of using regenerative cells in the treatment of inherited and acquired disorders of the bone, bone marrow, liver, and other tissues
US20030157110A1 (en) * 2002-01-07 2003-08-21 Millennium Pharmaceuticals, Inc. Methods for the treatment of metabolic disorders, including obesity and diabetes
ATE421328T1 (de) * 2002-02-22 2009-02-15 Intracel Recources Llc Sterile immunogene nicht-tumorigene tumorzell- zusammensetzungen und verfahren
US20050058641A1 (en) * 2002-05-22 2005-03-17 Siemionow Maria Z. Tolerance induction and maintenance in hematopoietic stem cell allografts
DE10242337A1 (de) * 2002-09-09 2004-03-18 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper zur Isolierung und/oder Identifizierung neuronaler Stammzellen und Verfahren zur Isolierung und/oder Identifizierung neuronaler Vorläuferzellen
GB0304030D0 (en) * 2003-02-21 2003-03-26 King S College London Teeth
JP2007535486A (ja) * 2003-05-07 2007-12-06 ラ ホーヤ インスティチュート フォー モレキュラー メディシン 高分子量のヒアルロン酸を用いた内因性又は埋め込まれた又は移植された幹細胞の機能回復を促進するための方法
US20050019801A1 (en) * 2003-06-04 2005-01-27 Curis, Inc. Stem cell-based methods for identifying and characterizing agents
EP2399990B1 (en) * 2003-06-27 2015-07-22 DePuy Synthes Products, Inc. Cells derived from post-partum umbilical cord for use in treatment of disease of the heart and circulatory system
US20050256077A1 (en) * 2004-03-30 2005-11-17 Henning Susan J Gastrointestinal stem cells and uses thereof
US20070253931A1 (en) * 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders

Also Published As

Publication number Publication date
US20140030235A1 (en) 2014-01-30
EP2262513A1 (en) 2010-12-22
US20100330052A1 (en) 2010-12-30
NZ587809A (en) 2012-08-31
US20130121975A1 (en) 2013-05-16
WO2009111030A1 (en) 2009-09-11
BRPI0909817A2 (pt) 2017-06-13
US20100291047A1 (en) 2010-11-18
CN102014936A (zh) 2011-04-13
US20120263687A1 (en) 2012-10-18
JP6037597B2 (ja) 2016-12-07
US20080286249A1 (en) 2008-11-20
CA2717498A1 (en) 2009-09-11
US20140322180A1 (en) 2014-10-30
JP2011514901A (ja) 2011-05-12
US20110177045A1 (en) 2011-07-21
MX2010009767A (es) 2010-09-28

Similar Documents

Publication Publication Date Title
AU2013205951B2 (en) Use of mesenchymal stem cells for treating genetic diseases and disorders
US20100330052A1 (en) Use of Mesenchymal Stem Cells for Treating Genetic Diseases and Disorders
Lohan et al. Anti-donor immune responses elicited by allogeneic mesenchymal stem cells and their extracellular vesicles: are we still learning?
Skuk et al. Myoblast transplantation: the current status of a potential therapeutic tool for myopathies
EP1727892B1 (en) Mesenchymal stem cells and uses therefor
KR20140048840A (ko) 초음파 캐비테이션 유도된 간질 또는 간엽 혈관 추출물 및 이로부터 유도되고 아디포스 조직으로부터 수득된 세포 및 이의 용도
BRPI0613190A2 (pt) imunofenótipo e imunogeniticidade de células humanas derivadas de adipose
Kizilay et al. Effect of systemic application of bone marrow-derived mesenchymal stem cells on healing of peripheral nerve injury in an experimental sciatic nerve injury model
Mohammedsaleh The use of patient-specific stem cells in different autoimmune diseases
Payne et al. The prospect of stem cells as multi-faceted purveyors of immune modulation, repair and regeneration in multiple sclerosis
Stoltz et al. Cell and tissue engineering and clinical applications: an overview
Garbuzova-Davis et al. Cord blood as a potential therapeutic for amyotrophic lateral sclerosis
Köse et al. Stem cell applications in lysosomal storage disorders: progress and ongoing challenges
ES2657382T5 (es) Células madre mesenquimales y usos de las mismas
AU2015201881A1 (en) Use of mesenchymal stem cells for treating genetic diseases and disorders
Turksen Stem cells: Current challenges and new directions
Xiong et al. Microdystrophin delivery in dystrophin-deficient (mdx) mice by genetically-corrected syngeneic MSCs transplantation
KR20230008250A (ko) 중간엽 줄기 세포 및 그에 대한 용도
KR20230140802A (ko) 줄기세포의 기능 강화용 조성물 및 이의 용도
Ripoll Adult stem cell therapy in the twitcher mouse model of Krabbe's disease utilizing mesenchymal lineage stem cells
Lau The effects of oxygen and glucose culture on mouse bone marrow mesenchymal stem cells
an Experimental Potently Immunosuppressive 5-Fluorouracil
Ilea et al. Post-transplantation distribution of CD44+ human mesenchymal stem cells in a mouse model.
Horwitz Future Directions in Pediatric Stem-Cell Transplantation

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: MESOBLAST INTERNATIONAL SARL

Free format text: FORMER APPLICANT(S): OSIRIS THERAPEUTICS, INC.

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted